JP2018518540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518540A5 JP2018518540A5 JP2018519261A JP2018519261A JP2018518540A5 JP 2018518540 A5 JP2018518540 A5 JP 2018518540A5 JP 2018519261 A JP2018519261 A JP 2018519261A JP 2018519261 A JP2018519261 A JP 2018519261A JP 2018518540 A5 JP2018518540 A5 JP 2018518540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- binding protein
- antigen
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117516A JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183297P | 2015-06-23 | 2015-06-23 | |
| US62/183,297 | 2015-06-23 | ||
| US201562266398P | 2015-12-11 | 2015-12-11 | |
| US62/266,398 | 2015-12-11 | ||
| PCT/US2016/039015 WO2016210129A1 (en) | 2015-06-23 | 2016-06-23 | Novel pd-1 immune modulating agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117516A Division JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518540A JP2018518540A (ja) | 2018-07-12 |
| JP2018518540A5 true JP2018518540A5 (cg-RX-API-DMAC10.html) | 2019-08-08 |
| JP6974311B2 JP6974311B2 (ja) | 2021-12-01 |
Family
ID=56373127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519261A Expired - Fee Related JP6974311B2 (ja) | 2015-06-23 | 2016-06-23 | 新規ｐｄ−１免疫調節剤 |
| JP2021117516A Ceased JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117516A Ceased JP2021177768A (ja) | 2015-06-23 | 2021-07-16 | 新規ｐｄ−１免疫調節剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11136392B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3313883B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6974311B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20180019725A (cg-RX-API-DMAC10.html) |
| CN (2) | CN108337890B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016281641B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3006224A1 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1254803A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL256463A (cg-RX-API-DMAC10.html) |
| TW (1) | TWI773647B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016210129A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| JP6974311B2 (ja) * | 2015-06-23 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | 新規ｐｄ−１免疫調節剤 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| MA43028B1 (fr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| WO2017133175A1 (en) * | 2016-02-04 | 2017-08-10 | Nanjing Legend Biotech Co., Ltd. | Engineered mammalian cells for cancer therapy |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| US20190334192A1 (en) * | 2016-12-19 | 2019-10-31 | Showa Denko K.K. | Method for operating redox flow cell |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| KR102461885B1 (ko) | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| CA3052532A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| UA128387C2 (uk) * | 2017-04-05 | 2024-07-03 | Ф. Хоффманн-Ля Рош Аг | Антитіло до lag3 |
| JP2020517263A (ja) * | 2017-04-19 | 2020-06-18 | ユニバーシティ オブ サザン カリフォルニア | がんを治療するための組成物及び方法 |
| WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| CN110809582B (zh) * | 2017-05-01 | 2023-12-22 | 儿童医疗中心有限公司 | 涉及抗pd1抗体试剂的方法以及组合物 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR20200037250A (ko) * | 2017-07-06 | 2020-04-08 | 메뤼스 엔.페. | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 |
| US11884934B2 (en) * | 2017-07-21 | 2024-01-30 | Washington University | Methods and compositions for T cell activation |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN111971059A (zh) * | 2018-01-31 | 2020-11-20 | 细胞基因公司 | 使用过继细胞疗法和检查点抑制剂的组合疗法 |
| CN112041432A (zh) | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| TWI708787B (zh) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| AU2019299555A1 (en) * | 2018-07-04 | 2021-02-25 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1 |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| CN111320690B (zh) * | 2018-12-17 | 2022-04-05 | 程联胜 | 一种抗人Tim3单克隆抗体及其应用 |
| CN111748580B (zh) * | 2019-03-28 | 2022-09-13 | 百奥泰生物制药股份有限公司 | 一种检测免疫检查点抗体活性的方法 |
| CN111892655B (zh) * | 2019-05-06 | 2022-10-28 | 四川大学 | 抗pd-1纳米抗体的筛选及应用 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| JP7680967B2 (ja) * | 2019-06-14 | 2025-05-21 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｐｄ－１に対する抗体およびその使用方法 |
| JP6881658B2 (ja) | 2019-07-05 | 2021-06-02 | 小野薬品工業株式会社 | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| WO2021011480A1 (en) * | 2019-07-12 | 2021-01-21 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind cxcr4 to modulate cellular function |
| WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| EP4013447A4 (en) * | 2019-08-16 | 2024-05-29 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | T CELLS EXPRESSING A CHIMERIC ANTI-CD83 ANTIGEN RECEPTOR |
| CN112852740A (zh) * | 2019-11-27 | 2021-05-28 | 深圳市菲鹏生物治疗股份有限公司 | Car-t细胞和检测方法 |
| WO2021133036A1 (ko) | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항-lilrb1 항체 및 그의 용도 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| CN114437229B (zh) * | 2020-11-01 | 2024-03-12 | 复旦大学 | 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途 |
| CN112812174A (zh) * | 2021-01-15 | 2021-05-18 | 新乡学院 | 猪pd-l14qn-af表位多肽及其应用 |
| CN115521378B (zh) * | 2021-07-23 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-l1抗体及其用途 |
| WO2024182754A2 (en) * | 2023-03-02 | 2024-09-06 | Fred Hutchinson Cancer Center | Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| WO2025085538A1 (en) * | 2023-10-17 | 2025-04-24 | Lanier Biotherapeutics, Inc. | Alarmin binding molecules and treatment of cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4834976A (en) * | 1986-07-03 | 1989-05-30 | Genetic Systems Corporation | Monoclonal antibodies to pseudomonas aeruginosa flagella |
| ES2367430T3 (es) * | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2008119565A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
| PT2170959E (pt) * | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| CN103965363B (zh) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| CN103242448B (zh) * | 2013-05-27 | 2015-01-14 | 郑州大学 | 一种全人源化抗pd-1单克隆抗体及其制备方法和应用 |
| CN104558177B (zh) * | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| WO2016090337A1 (en) * | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
| CN104479020B (zh) * | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
| TW201702272A (zh) * | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| JP6974311B2 (ja) * | 2015-06-23 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | 新規ｐｄ−１免疫調節剤 |
| PH12018501177B1 (en) * | 2015-12-04 | 2024-01-24 | Eureka Therapeutics Inc | Antibodies targeting fc receptor-like 5 and methods of use |
| US11505599B2 (en) * | 2016-01-14 | 2022-11-22 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for Foxp3-derived peptides |
| LT3535298T (lt) * | 2016-11-02 | 2021-12-27 | Jounce Therapeutics, Inc. | Antikūnai prieš pd-1 ir jų panaudojimas |
| JP2020536531A (ja) * | 2017-09-26 | 2020-12-17 | ロングウッド ユニバーシティーＬｏｎｇｗｏｏｄ Ｕｎｉｖｅｒｓｉｔｙ | 免疫療法としてのｐｄ１特異的キメラ抗原受容体 |
-
2016
- 2016-06-23 JP JP2018519261A patent/JP6974311B2/ja not_active Expired - Fee Related
- 2016-06-23 KR KR1020187002014A patent/KR20180019725A/ko not_active Withdrawn
- 2016-06-23 CA CA3006224A patent/CA3006224A1/en not_active Abandoned
- 2016-06-23 EP EP16736667.3A patent/EP3313883B1/en active Active
- 2016-06-23 TW TW105119709A patent/TWI773647B/zh not_active IP Right Cessation
- 2016-06-23 WO PCT/US2016/039015 patent/WO2016210129A1/en not_active Ceased
- 2016-06-23 HK HK18113888.8A patent/HK1254803A1/zh unknown
- 2016-06-23 CN CN201680037151.1A patent/CN108337890B/zh active Active
- 2016-06-23 CN CN202111160281.3A patent/CN114133448A/zh active Pending
- 2016-06-23 AU AU2016281641A patent/AU2016281641B2/en active Active
-
2017
- 2017-12-20 IL IL256463A patent/IL256463A/en unknown
- 2017-12-20 US US15/849,107 patent/US11136392B2/en active Active
-
2021
- 2021-07-16 JP JP2021117516A patent/JP2021177768A/ja not_active Ceased